Advertisement
PBH vs TAK
To compare these two companies we present long-term analysis, their fundamental ratings and make comparative short-term technical analysis which are presented below. The conclusion is PBH is a StrongBuy and TAK is a StrongBuy.
Momentum Indicator for PBH turns positive, indicating new upward trend
PBH saw its Momentum Indicator move above the 0 level on October 07, 2026. This is an indication that the stock could be shifting in to a new upward move. Traders may want to consider buying the stock or buying call options. Tickeron's A.I.dvisor looked at 83 similar instances where the indicator turned positive. In 51 of the 83 cases, the stock moved higher in the following days. The odds of a move higher are at 61%.
Technical Analysis (Indicators)
Bullish Trend Analysis
The RSI Oscillator points to a transition from a downward trend to an upward trend -- in cases where PBH's RSI Indicator exited the oversold zone, 23 of 40 resulted in an increase in price. Tickeron's analysis proposes that the odds of a continued upward trend are 57%.
The Moving Average Convergence Divergence (MACD) for PBH just turned positive on October 06, 2026. Looking at past instances where PBH's MACD turned positive, the stock continued to rise in 22 of 38 cases over the following month. The odds of a continued upward trend are 58%.
Following a +3.14% 3-day Advance, the price is estimated to grow further. Considering data from situations where PBH advanced for three days, in 168 of 320 cases, the price rose further within the following month. The odds of a continued upward trend are 52%.
The Aroon Indicator entered an Uptrend today. In 134 of 229 cases where PBH Aroon's Indicator entered an Uptrend, the price rose further within the following month. The odds of a continued Uptrend are 59%.
Bearish Trend Analysis
The Stochastic Oscillator may be shifting from an upward trend to a downward trend. In 37 of 63 cases where PBH's Stochastic Oscillator exited the overbought zone, the price fell further within the following month. The odds of a continued downward trend are 59%.
PBH moved below its 50-day moving average on October 21, 2026 date and that indicates a change from an upward trend to a downward trend.
Following a 3-day decline, the stock is projected to fall further. Considering past instances where PBH declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 58%.
PBH broke above its upper Bollinger Band on October 12, 2026. This could be a sign that the stock is set to drop as the stock moves back below the upper band and toward the middle band. You may want to consider selling the stock or exploring put options.
Fundamental Analysis (Ratings)
The Tickeron PE Growth Rating for this company is 47 (best 1 - 100 worst), pointing to consistent earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.
The Tickeron Price Growth Rating for this company is 55 (best 1 - 100 worst), indicating steady price growth. PBH’s price grows at a higher rate over the last 12 months as compared to S&P 500 index constituents.
The Tickeron Valuation Rating of 64 (best 1 - 100 worst) indicates that the company is fair valued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (1.184) is normal, around the industry mean (11.138). P/E Ratio (13.385) is within average values for comparable stocks, (-7.600). Projected Growth (PEG Ratio) (1.482) is also within normal values, averaging (2.152). Dividend Yield (0.000) settles around the average of (0.038) among similar stocks. P/S Ratio (2.042) is also within normal values, averaging (178.797).
The Tickeron SMR rating for this company is 74 (best 1 - 100 worst), indicating slightly better than average sales and a considerably profitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.
The Tickeron Seasonality Score of 75 (best 1 - 100 worst) indicates that the company is slightly overvalued in the industry. The Tickeron Seasonality score describes the variance of predictable price changes around the same period every calendar year. These changes can be tied to a specific month, quarter, holiday or vacation period, as well as a meteorological or growing season.
The Tickeron Profit vs. Risk Rating rating for this company is 100 (best 1 - 100 worst), indicating that the returns do not compensate for the risks. PBH’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 84, placing this stock worse than average.
TAK in upward trend: price rose above 50-day moving average on October 06, 2026
TAK moved above its 50-day moving average on October 06, 2026 date and that indicates a change from a downward trend to an upward trend. In 18 of 35 similar past instances, the stock price increased further within the following month. The odds of a continued upward trend are 51%.
Technical Analysis (Indicators)
Bullish Trend Analysis
The Momentum Indicator moved above the 0 level on October 13, 2026. You may want to consider a long position or call options on TAK as a result. In 41 of 95 past instances where the momentum indicator moved above 0, the stock continued to climb. The odds of a continued upward trend are 43%.
The Moving Average Convergence Divergence (MACD) for TAK just turned positive on October 14, 2026. Looking at past instances where TAK's MACD turned positive, the stock continued to rise in 17 of 43 cases over the following month. The odds of a continued upward trend are 40%.
Following a +3.47% 3-day Advance, the price is estimated to grow further. Considering data from situations where TAK advanced for three days, in 156 of 318 cases, the price rose further within the following month. The odds of a continued upward trend are 49%.
The Aroon Indicator entered an Uptrend today. In 104 of 273 cases where TAK Aroon's Indicator entered an Uptrend, the price rose further within the following month. The odds of a continued Uptrend are 38%.
Bearish Trend Analysis
The RSI Indicator demonstrates that the ticker has stayed in the overbought zone for 4 days. The longer the ticker stays in the overbought zone, the sooner a price pull-back is expected.
The Stochastic Oscillator demonstrated that the ticker has stayed in the overbought zone for 7 days. The longer the ticker stays in the overbought zone, the sooner a price pull-back is expected.
Following a 3-day decline, the stock is projected to fall further. Considering past instances where TAK declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 44%.
TAK broke above its upper Bollinger Band on October 15, 2026. This could be a sign that the stock is set to drop as the stock moves back below the upper band and toward the middle band. You may want to consider selling the stock or exploring put options.
Fundamental Analysis (Ratings)
The Tickeron Valuation Rating of 7 (best 1 - 100 worst) indicates that the company is seriously undervalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (0.008) is normal, around the industry mean (11.138). P/E Ratio (-0.381) is within average values for comparable stocks, (-7.600). Projected Growth (PEG Ratio) (0.425) is also within normal values, averaging (2.152). Dividend Yield (0.059) settles around the average of (0.038) among similar stocks. P/S Ratio (1.968) is also within normal values, averaging (178.797).
The Tickeron Profit vs. Risk Rating rating for this company is 37 (best 1 - 100 worst), indicating well-balanced risk and returns. The average Profit vs. Risk Rating rating for the industry is 84, placing this stock slightly better than average.
The Tickeron Price Growth Rating for this company is 39 (best 1 - 100 worst), indicating steady price growth. TAK’s price grows at a higher rate over the last 12 months as compared to S&P 500 index constituents.
The Tickeron SMR rating for this company is 91 (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.
The Tickeron PE Growth Rating for this company is 97 (best 1 - 100 worst), pointing to worse than average earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.
PBH | TAK | ||
|---|---|---|---|
OUTLOOK RATING 1..100 | 18 | 34 | |
VALUATION overvalued / fair valued / undervalued 1..100 | 64 Fair valued | 7 Undervalued | |
PROFIT vs RISK RATING 1..100 | 100 | 37 | |
SMR RATING 1..100 | 74 | 91 | |
PRICE GROWTH RATING 1..100 | 55 | 39 | |
P/E GROWTH RATING 1..100 | 47 | 97 | |
SEASONALITY SCORE 1..100 | 75 | 50 |
Tickeron ratings are formulated such that a rating of 1 designates the most successful stocks in a given industry, while a rating of 100 points to the least successful stocks for that industry.
TAK's Valuation (7) in the Pharmaceuticals Major industry is somewhat better than the same rating for PBH (64) in the Pharmaceuticals Other industry. This means that TAK’s stock grew somewhat faster than PBH’s over the last 12 months.
TAK's Profit vs Risk Rating (37) in the Pharmaceuticals Major industry is somewhat better than the same rating for PBH (100) in the Pharmaceuticals Other industry. This means that TAK’s stock grew somewhat faster than PBH’s over the last 12 months.
PBH's SMR Rating (74) in the Pharmaceuticals Other industry is in the same range as TAK (91) in the Pharmaceuticals Major industry. This means that PBH’s stock grew similarly to TAK’s over the last 12 months.
TAK's Price Growth Rating (39) in the Pharmaceuticals Major industry is in the same range as PBH (55) in the Pharmaceuticals Other industry. This means that TAK’s stock grew similarly to PBH’s over the last 12 months.
PBH's P/E Growth Rating (47) in the Pharmaceuticals Other industry is somewhat better than the same rating for TAK (97) in the Pharmaceuticals Major industry. This means that PBH’s stock grew somewhat faster than TAK’s over the last 12 months.
| PBH | TAK | |
|---|---|---|
| RSI ODDS (%) | 2 days ago 57% | 2 days ago 27% |
| Stochastic ODDS (%) | 2 days ago 59% | 2 days ago 41% |
| Momentum ODDS (%) | 2 days ago 61% | 2 days ago 43% |
| MACD ODDS (%) | 2 days ago 58% | 2 days ago 40% |
| TrendWeek ODDS (%) | 2 days ago 60% | 2 days ago 47% |
| TrendMonth ODDS (%) | 2 days ago 55% | 2 days ago 48% |
| Advances ODDS (%) | 7 days ago 52% | 7 days ago 49% |
| Declines ODDS (%) | 2 days ago 58% | 10 days ago 44% |
| BollingerBands ODDS (%) | 2 days ago 76% | 2 days ago 39% |
| Aroon ODDS (%) | 2 days ago 59% | 2 days ago 38% |
Long-Term Analysis
It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is overvalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).
PBH’s FA Score shows that 0 FA rating(s) are green while TAK’s FA Score has 1 green FA rating(s).
- PBH’s FA Score: 0 green, 5 red.
- TAK’s FA Score: 1 green, 4 red.
Short-Term Analysis
It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.
If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.
PBH’s TA Score shows that 5 TA indicator(s) are bullish while TAK’s TA Score has 5 bullish TA indicator(s).
- PBH’s TA Score: 5 bullish, 4 bearish.
- TAK’s TA Score: 5 bullish, 4 bearish.
Price Growth
PBH (@Pharmaceuticals: Generic) experienced а -0.99% price change this week, while TAK (@Pharmaceuticals: Generic) price change was +4.84% for the same time period.
The average weekly price growth across all stocks in the @Pharmaceuticals: Generic industry was -2.94%. For the same industry, the average monthly price growth was -9.84%, and the average quarterly price growth was +9.53%.
Reported Earning Dates
PBH is expected to report earnings on Nov 05, 2026.
TAK is expected to report earnings on Oct 29, 2026.
Industries' Descriptions
@Pharmaceuticals: Generic (-2.94% weekly)A generic drug contains the same chemical substance as a drug that was originally protected by patents. Generic drugs are generally sold at cheaper price points, compared to name-brand pharmaceuticals, after patents for the more expensive drugs lapse. The generic drug industry has created a major market, thanks to the lower pricing. According to the Center for Justice and Democracy at New York Law School, 80 percent of all drugs prescribed are generic, and generic drugs are chosen 94 percent of the time when they are available. But their manufacturers must be able to prove to the FDA that they can be effective substitutes for the original drugs. Some of the major generic drug makers include Zoetis, Inc., Allergan plc and Mylan N.V.
Advertisement
PBH and
Correlation & Price change
A.I.dvisor indicates that over the last year, PBH has been loosely correlated with HLN. These tickers have moved in lockstep 37% of the time. This A.I.-generated data suggests there is some statistical probability that if PBH jumps, then HLN could also see price increases.
| Ticker / NAME | Correlation To PBH | 1D Price Change % | ||
|---|---|---|---|---|
| PBH | 100% | -2.92% | ||
| HLN - PBH | 37% Loosely correlated | -1.47% | ||
| PRGO - PBH | 35% Loosely correlated | -1.61% | ||
| AMPH - PBH | 32% Poorly correlated | +1.00% | ||
| ANIP - PBH | 31% Poorly correlated | -0.59% | ||
| ELAN - PBH | 29% Poorly correlated | -0.66% | ||
More | ||||
TAK and
Correlation & Price change
A.I.dvisor indicates that over the last year, TAK has been loosely correlated with HLN. These tickers have moved in lockstep 47% of the time. This A.I.-generated data suggests there is some statistical probability that if TAK jumps, then HLN could also see price increases.
| Ticker / NAME | Correlation To TAK | 1D Price Change % | ||
|---|---|---|---|---|
| TAK | 100% | -0.75% | ||
| HLN - TAK | 47% Loosely correlated | -1.47% | ||
| COLL - TAK | 29% Poorly correlated | -1.36% | ||
| ANIK - TAK | 28% Poorly correlated | +0.78% | ||
| PRGO - TAK | 28% Poorly correlated | -1.61% | ||
| PBH - TAK | 28% Poorly correlated | -2.92% | ||
More | ||||